You are here

Approvals, Launches, and New Indications

Resorbable Dextenza is the First Intracanalicular Insert for Drug Delivery
First Biosimilar For Adults With CD20-Positive, B-Cell Non-Hodgkin’s Lymphoma
First Drug for Rare Autoimmune Disorder That Affects Nerve, Muscles Connection
Hope For Patients With Highly Aggressive Form of AML
Oncology Therapy for Adult and Pediatric Tumors With a Neurotrophic Receptor Tyrosine Kinase (NTRK) Gene Fusion
First Hedgehog Pathway Inhibitor Approved for AML in Adults Aged 75 and Older
First and Only Treatment for Rare Hyper-Inflammation Syndrome With High Mortality
First-Line Treatment for People With Life-Threatening Blood Disorder
First Once-Daily, Nebulized Bronchodilator Available at End of 2018
AI Software Helps Physicians Prioritize Patients with Hemorrhagic Stroke or Intracranial Trauma